Evidence map›Paper›PMID 41116060›Full record

ArticleThe EMBO journal2025

TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence.

Jennifer Kahlhofer, Nikolas Marchet, Kristian Zubak, Brigitta Seifert, Madlen Hotze, Anna-Sophia Egger-Hörschinger, Lucija Kucej, Claudia Manzl, Yannick Weyer, Sabine Weys and 20 more

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jennifer Kahlhofer *Institute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-7686-9488
Nikolas Marchet *Institute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Kristian ZubakInstitute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Brigitta SeifertInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0009-0005-3987-2126
Madlen HotzeDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0009-0001-1816-2089
Anna-Sophia Egger-HörschingerDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-5204-7121
Lucija KucejInstitute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0009-0000-1982-6919
Claudia ManzlInstitute of Neuropathology & Neuromolecular Pathology, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Yannick WeyerInstitute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-2612-6774
Sabine WeysInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Martin OffterdingerInstitute of Systems Neuroscience, BioOptics core facility, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0003-3396-7042
Sebastian HerzogInstitute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0001-7167-3489
Veronika ReitererInstitute of Pathophysiology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Chiara VolaniDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0003-3600-4735
Marcel KwiatkowskiDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-5804-6031
Saskia B WortmannUniversity Children's Hospital, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, 5020, Austria.ORCID http://orcid.org/0000-0002-1968-8103
Siamak NematiKinder- und Jugendheilkunde, Krankenhaus St. Vinzenz Zams, Zams, 6511, Austria.
Johannes A MayrUniversity Children's Hospital, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, 5020, Austria.ORCID http://orcid.org/0000-0001-6970-336X
Johannes ZschockeInstitute of Human Genetics, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-0046-8274
Bernhard RadlingerDepartment of Internal Medicine I, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Kathrin ThedieckDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, 6020, Austria.
Leopold KremserInstitute of Medical Biochemistry, Protein Core Facility, Medical University of Innsbruck, Innsbruck, Austria.
Bettina SargInstitute of Medical Biochemistry, Protein Core Facility, Medical University of Innsbruck, Innsbruck, Austria.
Lukas A HuberInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0003-1116-2120
Hesso FarhanInstitute of Pathophysiology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-0889-8463
Mariana E G de AraujoInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0003-0576-2680
Susanne KaserDepartment of Internal Medicine I, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0003-2524-5218
Sabine Scholl-BürgiDepartment of Child and Adolescent Health, Division of Pediatrics I-Inherited Metabolic Disorders, Medical University of Innsbruck, Innsbruck, 6020, Austria.
Daniela KarallDepartment of Child and Adolescent Health, Division of Pediatrics I-Inherited Metabolic Disorders, Medical University of Innsbruck, Innsbruck, 6020, Austria.ORCID http://orcid.org/0000-0002-4846-1047
David TeisInstitute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, 6020, Austria. david.teis@i-med.ac.at.ORCID http://orcid.org/0000-0002-8181-0253

Funding

Austrian Academy of Sciences DOC FellowshipAustrian Science Fund (FWF) 10.55776/DOC82Austrian Science Fund (FWF) 10.55776/FG20Austrian Science Fund (FWF) 10.55776/P30196Austrian Science Fund (FWF) 10.55776/P35832,10.55776/P36600,10.55776/FG20Austrian Science Fund (FWF) 10.55776/P35874,10.55776/P34907,10.55776/FG20,10.55776/DOC82Austrian Science Fund (FWF) 10.55776/P36925Deutsche Forschungsgemeinschaft (DFG) TH 1358/3e2EC | ERC | HORIZON EUROPE European Research Council (ERC) 101054429EC | Horizon 2020 Framework Programme (H2020) MESI-STRAT
6 · The paper itself

Abstract

Entry into and exit from cellular quiescence require dynamic adjustments in nutrient acquisition, yet the mechanisms by which quiescent cells downregulate amino acid (AA) transport remain poorly understood. Here we show that cells entering quiescence selectively target plasma membrane-resident amino acid transporters for endocytosis and lysosomal degradation. This process matches amino acid uptake with reduced translational demand and promotes survival during extended periods of quiescence. Mechanistically, we identify the α-arrestin TXNIP as a key regulator of this metabolic adaptation, since it mediates the endocytosis of the SLC7A5-SLC3A2 (LAT1-4F2hc) AA transporter complex in response to reduced AKT signaling. To promote transporter ubiquitination, TXNIP interacts with NEDD4L and other HECT-type ubiquitin ligases. Loss of TXNIP disrupts this regulation, resulting in dysregulated amino acid uptake, sustained mTORC1 signaling, and ultimately cell death under prolonged quiescence. The characterization of a novel TXNIP loss-of-function variant in a patient with a severe metabolic disease further supports its role in nutrient homeostasis and human health. Together, these findings highlight TXNIP's central role in controlling nutrient acquisition and metabolic plasticity with implications for quiescence biology and diseases.

Indexed as

Amino AcidsCarrier ProteinsEndocytosisLarge Neutral Amino Acid-Transporter 1AnimalsFusion Regulatory Protein 1, Heavy ChainHEK293 CellsHumansLysosomesMechanistic Target of Rapamycin Complex 1Nedd4 Ubiquitin Protein LigasesSignal TransductionUbiquitinationAmino AcidsCarrier ProteinsFusion Regulatory Protein 1, Heavy ChainLarge Neutral Amino Acid-Transporter 1Mechanistic Target of Rapamycin Complex 1Nedd4L protein, humanNedd4 Ubiquitin Protein LigasesSLC3A2 protein, humanSLC7A5 protein, humanTXNIP protein, humanAmino Acids UptakeEndocytosisQuiescenceSLC7A5/LAT1TXNIP

Identifiers

PMID41116060
PMCPMC12669767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.